Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | XBP1 | P17861 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | KCNN4 | O15554 | 4/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | PYCR1 | P32322 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8585838 | 0.81 | PYCR1 (0.43) | PYCR1ALDH1A1 | |
| SCHEMBL186944 | 0.77 | RAB9A (0.41) | RAB9ASMN1; SMN2MEN1NPC1MAPT | |
| SCHEMBL26394736 | 0.76 | SLC6A3 (0.32) | — | |
| SCHEMBL8585783 | 0.76 | MEN1 (0.50) | RAB9ASMN1; SMN2MEN1NPC1MAPK1 | |
| SCHEMBL18396557 | 0.76 | RAB9A (0.41) | RAB9ASMN1; SMN2MEN1NPC1MAPT | |
| SCHEMBL2534039 | 0.76 | RAB9A (0.37) | RAB9ASMN1; SMN2MEN1NPC1MAPT | |
| SCHEMBL9454463 | 0.76 | RAB9A (0.37) | RAB9ASMN1; SMN2MEN1NPC1MAPT | |
| SCHEMBL131037 | 0.75 | MAPK1 (0.44) | MAPTMAPK1KMT2AKCNN4ALDH1A1 | |
| SCHEMBL24278471 | 0.74 | RAB9A (0.36) | RAB9ASMN1; SMN2MEN1NPC1MAPT | |
| SCHEMBL26394766 | 0.74 | KCNN4 (0.43) | RAB9ANPC1KMT2AACHEKCNN4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230314944-A1 | POSITIVE RESIST COMPOSITION AND PATTERN FORMING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-10-05 | — | — | US | disclosed |
| US-20230314944-A1 | POSITIVE RESIST COMPOSITION AND PATTERN FORMING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-10-05 | — | — | US | disclosed |
| US-9023864-B2 | Indole derivatives as CRTH2 receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2015-05-05 | — | — | US | disclosed |
| EP-2492267-B1 | Indole derivatives as CRTH2 receptor antagonists in combination with a second active ingredient | MERCK SHARP & DOHME (US) | 2014-11-26 | — | — | EP | disclosed |
| EP-2401269-B1 | INDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2014-01-29 | — | — | EP | disclosed |
| US-20130150398-A1 | Indole Derivatives as CRTH2 Receptor Antagonists | MERCK SHARP & DOHME LLC | 2013-06-13 | — | — | US | disclosed |
| US-8394819-B2 | Indole derivatives as CRTH2 receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-03-12 | — | — | US | disclosed |
| EP-2492267-A1 | Indole derivatives as CRTH2 receptor antagonists in combination with a second active ingredient | Merck Sharp & Dohme Corp. (US) | 2012-08-29 | — | — | EP | disclosed |
| EP-2401269-A1 | INDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | Merck Sharp & Dohme Corp. (US) | 2012-01-04 | — | — | EP | disclosed |
| US-20100234415-A1 | INDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2010-09-16 | — | — | US | disclosed |
| WO-2010099039-A1 | INDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2010-09-02 | — | — | WO | disclosed |
| US-5030625-A | Applying to phytopathogen | SANDOZ LTD. (CH) | 1991-07-09 | — | — | US | disclosed |
| EP-0191269-B1 | NOVEL HOMOPROPARGYLAMINES | SANDOZ AG (CH) | 1991-03-06 | — | — | EP | disclosed |
| US-4684661-A | Anti-fungal homopropargylamines, compositions, and method of use therefor | SANDOZ LTD. (CH) | 1987-08-04 | — | — | US | disclosed |
| EP-0191269-A2 | Novel homopropargylamines | SANDOZ AG (CH) | 1986-08-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150398-A1 | Indole Derivatives as CRTH2 Receptor Antagonists | PTGER2, PTGDR2, PTGDR | RAB9A 3377/4885SMN1; SMN2 4820/4885MEN1 4370/4885 |
| US-20100234415-A1 | INDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | PTGER2, PTGDR2, PTGDR | RAB9A 3377/4885SMN1; SMN2 4820/4885MEN1 4370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.